Global Alliance for TB Drug Development
http://www.tballiance.org/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Global Alliance for TB Drug Development
J&J Pledges $500m To Eliminate HIV and TB
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
US FDA's Antimicrobial Head Ed Cox Leaves For Regeneron; Agency Needs New LPAD Champion
Long-time deputy John Farley becomes acting director of the Office of Antimicrobial Products. Cox, who served as the director of the office for more than a decade, joins Regeneron to serve as vice president of regulatory affairs.
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Pink Sheet Podcast: Zolgensma Saga Continues, ICER Reviews DMD Drugs, FDA Issues Another LPAD Approval
Pink Sheet reporters review Novartis' latest response to Zolgensma data manipulation, discuss ICER reviews of Sarepta's Duchenne muscular dystrophy treatments, and recap the FDA's latest antibiotic approval.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- TB Alliance
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice